bevacizumab-maly 100 MG in 4 ML Injection

RxCUI: 2599043
RxNorm name: bevacizumab-maly 100 MG in 4 ML Injection
Display name: bevacizumab-maly 100 MG in 4 ML Injection
Full name: bevacizumab-maly 100 MG in 4 ML Injection
Term type: PSN
Status: DailyMed mapping
Updated: 2026-06-04 23:39:02

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLA	Proprietary name	Proper name	License type	Status	Latest source
761231	Alymsys	bevacizumab-maly	351(k) Biosimilar	Rx	2026-07-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
ALYMSYS	BEVACIZUMAB-MALY	Amneal Pharmaceuticals LLC	6b4040a2-a5c5-4ff0-ab45-935d7e49cf78	2026-03-23	Warnings, Adverse reactions	Exact identifier rxcui: 2599043
ALYMSYS	BEVACIZUMAB-MALY	Valorum Biologics, LLC	42b4f96e-1f70-2126-e063-6294a90a93e3	2026-01-27	Warnings, Adverse reactions	Exact identifier rxcui: 2599043

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 2 matching rows.

Set ID, RxNorm mappings, Terms table
Set ID	RxNorm mappings	Terms	SPL version	Label	Effective
6b4040a2-a5c5-4ff0-ab45-935d7e49cf78	bevacizumab-maly 100 MG in 4 ML Injection [PSN] · 4 ML bevacizumab-maly 25 MG/ML Injection [SCD] · bevacizumab-maly 100 MG per 4 ML Injection [SY] · bevacizumab-maly 25 MG/ML per 4 ML Injection [SY]	4	9	These highlights do not include all the information needed to use ALYMSYS safely and effectively. See full prescribing information for ALYMSYS . ALYMSYS ® (bevacizumab-maly) injection, for intravenous use Initial U.S. Approval: 2022 ALYMSYS (bevacizumab-maly) is biosimilar* to AVASTIN (bevacizumab)	20260323
42b4f96e-1f70-2126-e063-6294a90a93e3	bevacizumab-maly 100 MG in 4 ML Injection [PSN] · 4 ML bevacizumab-maly 25 MG/ML Injection [SCD] · bevacizumab-maly 100 MG per 4 ML Injection [SY] · bevacizumab-maly 25 MG/ML per 4 ML Injection [SY]	4	7	These highlights do not include all the information needed to use ALYMSYS safely and effectively. See full prescribing information for ALYMSYS . ALYMSYS ® (bevacizumab-maly) injection, for intravenous use Initial U.S. Approval: 2022 ALYMSYS (bevacizumab-maly) is biosimilar* to AVASTIN (bevacizumab)	20260127